BF Biosciences Delivers Strong Financial Performance in FY2026

BF Biosciences Limited posted a strong financial performance for the year ended June 30, 2026, with significant growth in revenue, gross profit and earnings. The company’s latest financial statements show that improved business performance translated into higher profitability despite continued finance and taxation costs. 283670

Revenue rises sharply

According to the financial statements, BF Biosciences recorded net revenue of Rs9.46 billion in FY2026, compared with Rs5.84 billion in the previous year. This represents an increase of approximately 62%, highlighting substantial growth in the company’s top line. 283670

The stronger revenue performance also supported a significant improvement in gross profit. Gross profit increased to Rs4.09 billion, compared with Rs2.29 billion in FY2025, an increase of nearly 79%.

Profitability improves

BF Biosciences reported profit from operations of Rs1.17 billion, up from Rs851.4 million a year earlier. After finance costs, minimum tax and income tax, the company posted profit after taxation of Rs632.1 million, compared with Rs447.1 million in FY2025.

This translates into an annual profit increase of approximately 41%, indicating that the company was able to convert its higher sales into stronger bottom-line earnings. 283670

The company’s earnings per share also improved to Rs7.16 from Rs5.52, providing another indication of stronger earnings attributable to shareholders.

Equity strengthens

BF Biosciences’ financial position also showed improvement during the year. Total equity increased to approximately Rs5.29 billion as of June 30, 2026, compared with Rs4.66 billion at the end of FY2025. The increase was supported by the year’s profit, which lifted unappropriated profit to approximately Rs3.25 billion. 283670

The statement of changes in equity confirms that the company closed FY2026 with total equity of Rs5.294 billion, compared with Rs4.662 billion a year earlier. 283670

Cash flows remain an area to watch

While profitability was strong, the cash-flow statement presents a more mixed picture. BF Biosciences generated approximately Rs1.49 billion in cash from operations before working-capital changes, but after changes in working capital and other payments, net cash used in operating activities stood at about Rs26.5 million during FY2026. 283670

The company also recorded significant investing cash inflows during the year, while financing activities resulted in a net cash outflow of approximately Rs318.9 million. Cash and cash equivalents stood at approximately Rs249.3 million at June 30, 2026.

Overall outlook

BF Biosciences’ FY2026 results present a positive picture from a profitability perspective. Strong revenue growth, higher gross profit, improved operating earnings and a 41% rise in profit after tax demonstrate considerable improvement compared with the previous financial year.

At the same time, movements in working capital, borrowings and cash generation will remain important factors for investors and stakeholders to monitor going forward. The balance sheet shows long-term secured loans of approximately Rs1.00 billion, while short-term secured borrowings increased during the year. 283670

Overall, FY2026 was a year of substantial earnings growth for BF Biosciences, with revenue reaching Rs9.46 billion and profit after tax rising to Rs632.1 million. The company’s ability to sustain revenue growth while maintaining profitability and strengthening its equity base will be key to its future financial performance.